In light of the important role of DCs in the induction of (antitumor) T-cell responses and the well-established role of Fscn1 for the functional activity of activated DC in migration and T-cell activation, the intent of this investigation is to elucidate the impact of Fscn1 inhibitors developed for tumor therapy with DCs. The gene discussed is FSCN1; the disease is neoplasm.